Rita Colorito | Authors


Perioperative Nivolumab/Ipilimumab Combo Showing Early Promising Results in HCC

September 24, 2019

Pathologic complete responses were seen in 29% of patients with resectable hepatocellular carcinoma treated with a perioperative immunotherapy regimen in the first interim analysis of a phase II trial, reported Yehia I. Abugabal, MD, in his presentation at the 2019 ILCA Annual Conference.

Atezolizumab Plus Bevacizumab Offers a Promising Option for Unresectable HCC

September 23, 2019

Clinically meaningful and durable objective responses were observed in the phase Ib subgroup efficacy analysis of atezolizumab plus bevacizumab in patients with previously untreated, unresectable hepatocellular carcinoma.

Second-Line Pembrolizumab Confers Improved OS, PFS in Patients With Advanced HCC

September 22, 2019

The final analysis of KEYNOTE-240, a phase III study of pembrolizumab in advanced hepatocellular cancer, demonstrated favorable benefit in overall survival and progression-free survival, according to Richard S. Finn, MD, during his presentation at the 13th Annual Conference of the International Liver Cancer Association in Chicago.

AFP Response Could Assist in Cabozantinib Therapy Selection in HCC

September 22, 2019

Patients with advanced hepatocellular carcinoma treated with cabozantinib had higher alpha-fetoprotein response rates versus those treated with placebo, according to findings of a subanalysis of the phase III CELESTIAL trial.

Safety of Nivolumab/Ipilimumab Combination Confirmed for Advanced HCC

September 21, 2019

For those with advanced hepatocellular carcinoma, the CheckMate 040 study found that the combination can be effective. Information from that study found that the combination can also yield a favorable safety profile, said Anthony B. El-Khoueiry, MD, in his presentation at the 2019 ILCA Annual Conference.